Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Launched by ASTRAZENECA · Aug 10, 2009
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histological or cytological confirmation of locally advanced or metastatic Non Small Cell Lung Cancer (IIIB-IV)
- • Tumour sample (block of slides) available for KRAS analysis
- Exclusion Criteria:
- • Confirmation of locally advanced or metastatic NSCLC (IIIB-IV) exclusively by cytology, with no tumour sample access.
- • Previous treatment using a MEK inhibitor or any other regimen containing docetaxel (previous treatment with paclitaxel is accepted)
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Belo Horizonte, , Brazil
Porto Alegre, , Brazil
Rio De Janeiro, , Brazil
Santo André, , Brazil
São Paulo, , Brazil
Patients applied
Trial Officials
José Eduardo Pipolo das Neves, MD
Study Director
AstraZeneca do Brasil, MC Medical Director
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials